Skip to main content
SpringerLink
Log in
Book cover

Molecular Pathology of Liver Diseases pp 499–509Cite as

Nonalcoholic Fatty Liver Disease

  • Chapter
  • First Online:

  • 3727 Accesses

Part of the book series: Molecular Pathology Library ((MPLB,volume 5))

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in North America, affecting approximately 30% of the population [1]. It is the hepatic manifestation of the metabolic syndrome, and is directly linked to the escalating prevalence of obesity and the associated insulin resistance. Histologically, NAFLD is characterized by a spectrum that ranges from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH) which can progress to cirrhosis in 15–20% of subjects [2]. NASH is further distinguished from NAFL by the presence of inflammation and cytologic ballooning with or without Mallory hyaline or pericellular fibrosis in addition to steatosis [3]. Recently, studies have reported that NAFLD may predispose patients to hepatocellular carcinoma (HCC) in the absence of significant fibrosis or cirrhosis, and these subjects also seem to have more features of the metabolic syndrome [4].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387–95.

    Article  PubMed  Google Scholar 

  2. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865–73.

    Article  PubMed  CAS  Google Scholar 

  3. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.

    Article  PubMed  Google Scholar 

  4. Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009;49(3):851–9.

    Article  PubMed  Google Scholar 

  5. Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007;46(4):1081–90.

    Article  PubMed  CAS  Google Scholar 

  6. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343–51.

    PubMed  CAS  Google Scholar 

  7. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med. 2004;10(4):355–61.

    Article  PubMed  CAS  Google Scholar 

  8. Matsusue K, Haluzik M, Lambert G, et al. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest. 2003;111(5):737–47.

    PubMed  CAS  Google Scholar 

  9. Magana MM, Lin SS, Dooley KA, Osborne TF. Sterol regulation of acetyl coenzyme A carboxylase promoter requires two interdependent binding sites for sterol regulatory element binding proteins. J Lipid Res. 1997;38(8):1630–8.

    PubMed  CAS  Google Scholar 

  10. Zhang YL, Hernandez-Ono A, Siri P, et al. Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. J Biol Chem. 2006;281(49):37603–15.

    Article  PubMed  CAS  Google Scholar 

  11. Ren D, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS. PPAR gamma knockdown by engineered transcription factors: exogenous PPAR gamma 2 but not PPAR gamma 1 reactivates adipogenesis. Genes Develop. 2002;16:27–32.

    Article  PubMed  CAS  Google Scholar 

  12. Yu S, Matsusue K, Kashireddy P, et al. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem. 2003;278(1):498–505.

    Article  PubMed  CAS  Google Scholar 

  13. Cha JY, Repa JJ. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem. 2007;282(1):743–51.

    Article  PubMed  CAS  Google Scholar 

  14. James WP. WHO comparative quantification of health risks. Chapter 8. Overweight and obesity. 2003; 1.

    Google Scholar 

  15. Prunet-Marcassus B, Cousin B, Caton D, Andre M, Penicaud L, Casteilla L. From heterogeneity to plasticity in adipose tissues: site-specific differences. Exp Cell Res. 2006;312(6):727–36.

    Article  PubMed  CAS  Google Scholar 

  16. Curat CA, Wegner V, Sengenes C, et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 2006;49(4):744–7.

    Article  PubMed  CAS  Google Scholar 

  17. Gu N, Guo XR, Ni YH, Liu F, Fei L, Chen RH. Overexpression of resistin affect 3T3-L1 adipocyte lipid metabolism. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2007;24(3):251–5.

    PubMed  CAS  Google Scholar 

  18. Ort T, Arjona AA, MacDougall JR, et al. Recombinant human FIZZ3/resistin stimulates lipolysis in cultured human adipocytes, mouse adipose explants, and normal mice. Endocrinology. 2005;146(5):2200–9.

    Article  PubMed  CAS  Google Scholar 

  19. Reddy JK, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr. 2001;21:193–230.

    Article  PubMed  CAS  Google Scholar 

  20. Ekstrom G, Ingelman-Sundberg M. Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1). Biochem Pharmacol. 1989;38(8):1313–9.

    Article  PubMed  CAS  Google Scholar 

  21. Fan CY, Pan J, Usuda N, Yeldandi AV, Rao MS, Reddy JK. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J Biol Chem. 1998;273(25):15639–45.

    Article  PubMed  CAS  Google Scholar 

  22. Rao MS, Reddy JK. PPARalpha in the pathogenesis of fatty liver disease. Hepatology. 2004;40(4):783–6.

    Article  PubMed  CAS  Google Scholar 

  23. Seo YS, Kim JH, Jo NY, et al. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J Gastroenterol Hepatol. 2008;23(1):102–9.

    PubMed  CAS  Google Scholar 

  24. Harano Y, Yasui K, Toyama T, et al. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int. 2006;26(5):613–20.

    Article  PubMed  CAS  Google Scholar 

  25. Nagle CA, Klett EL, Coleman RA. Hepatic triacylglycerol accumulation and insulin resistance. J Lipid Res. 2009;50(Suppl):S74–79.

    PubMed  Google Scholar 

  26. Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine (Baltimore). 2003;82(2):129–46.

    Article  Google Scholar 

  27. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes. 2003;52(7):1779–85.

    Article  PubMed  CAS  Google Scholar 

  28. Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab. 2003;285(3):E527–533.

    PubMed  CAS  Google Scholar 

  29. Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 2001;15(20):2654–9.

    Article  PubMed  CAS  Google Scholar 

  30. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996;271(5249):665–8.

    Article  PubMed  CAS  Google Scholar 

  31. Green A, Rumberger JM, Stuart CA, Ruhoff MS. Stimulation of lipolysis by tumor necrosis factor-alpha in 3T3-L1 adipocytes is glucose dependent: implications for long-term regulation of lipolysis. Diabetes. 2004;53(1):74–81.

    Article  PubMed  CAS  Google Scholar 

  32. Bruce CR, Dyck DJ. Cytokine regulation of skeletal muscle fatty acid metabolism: effect of interleukin-6 and tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab. 2004;287(4):E616–621.

    Article  PubMed  CAS  Google Scholar 

  33. Hawkins M, Tonelli J, Kishore P, et al. Contribution of elevated free fatty acid levels to the lack of glucose effectiveness in type 2 diabetes. Diabetes. 2003;52(11):2748–58.

    Article  PubMed  CAS  Google Scholar 

  34. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389–462.

    Article  PubMed  CAS  Google Scholar 

  35. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115(5):1298–305.

    PubMed  CAS  Google Scholar 

  36. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–54.

    Article  PubMed  CAS  Google Scholar 

  37. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002;12(9):735–9.

    Article  PubMed  CAS  Google Scholar 

  38. Houbaviy HB, Murray MF, Sharp PA. Embryonic stem cell-specific MicroRNAs. Dev Cell. 2003;5(2):351–8.

    Article  PubMed  CAS  Google Scholar 

  39. Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3(2):87–98.

    Article  PubMed  CAS  Google Scholar 

  40. Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T. The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem. 2007;282(11):8256–64.

    Article  PubMed  CAS  Google Scholar 

  41. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science. 2004;303(5654):95–8.

    Article  PubMed  CAS  Google Scholar 

  42. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary microRNAs by the Microprocessor complex. Nature. 2004;432(7014):231–5.

    Article  PubMed  CAS  Google Scholar 

  43. Cheung O, Puri P, Eicken C, et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology. 2008;48(6):1810–20.

    Article  PubMed  CAS  Google Scholar 

  44. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438(7068):685–9.

    Article  PubMed  Google Scholar 

  45. Esau C, Kang X, Peralta E, et al. MicroRNA-143 regulates adipocyte differentiation. J Biol Chem. 2004;279(50):52361–5.

    Article  PubMed  CAS  Google Scholar 

  46. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123(5):1705–25.

    Article  PubMed  Google Scholar 

  47. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120(5):1183–92.

    Article  PubMed  CAS  Google Scholar 

  48. Chalasani N, Gorski JC, Asghar MS, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology. 2003;37(3):544–50.

    Article  PubMed  CAS  Google Scholar 

  49. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114(12):1752–61.

    PubMed  CAS  Google Scholar 

  50. Yin H, Porter NA. New insights regarding the autoxidation of polyunsaturated fatty acids. Antioxid Redox Signal. 2005;7(1–2):170–84.

    Article  PubMed  CAS  Google Scholar 

  51. Kukoba TV, Shysh AM, Moibenko OO, Kotsiuruba AV, Kharchenko OV. The effects of omega-3 polyunsaturated fatty acids on lipid peroxidation. Fiziol Zh. 2005;51(1):26–32.

    PubMed  CAS  Google Scholar 

  52. Sweeney B, Puri P, Reen DJ. Modulation of immune cell function by polyunsaturated fatty acids. Pediatr Surg Int. 2005;21(5):335–40.

    Article  PubMed  Google Scholar 

  53. Wu X, Zhang L, Gurley E, et al. Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetinic acid through lysosomal and mitochondrial pathways. Hepatology. 2008;47(6):1905–15.

    Article  PubMed  CAS  Google Scholar 

  54. Pusl T, Wild N, Vennegeerts T, et al. Free fatty acids sensitize hepatocytes to bile acid-induced apoptosis. Biochem Biophys Res Commun. 2008;371(3):441–5.

    Article  PubMed  CAS  Google Scholar 

  55. Puri P, Mirshahi F, Natarajan R, Maher JW, Kellum JM, Sanyal AJ. Differential activation and dysregulation of unfolded protein response (UPR) in nonalcoholic fatty liver disease (NAFLD). Hepatology. 2006;44(S1:213A).

    Google Scholar 

  56. Puri P, Mirshahi F, Cheung O, et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology. 2008;134(2):568–76.

    Article  PubMed  CAS  Google Scholar 

  57. Malhi H, Bronk SF, Werneburg NW, Gores GJ. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem. 2006;281(17):12093–101.

    Article  PubMed  CAS  Google Scholar 

  58. Ferrante Jr AW. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J Intern Med. 2007;262(4):408–14.

    Article  PubMed  CAS  Google Scholar 

  59. Nomiyama T, Perez-Tilve D, Ogawa D, et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest. 2007;117(10):2877–88.

    Article  PubMed  CAS  Google Scholar 

  60. Stienstra R, Duval C, Keshtkar S, van der Laak J, Kersten S, Muller M. Peroxisome proliferator-activated receptor gamma activation promotes infiltration of alternatively activated macrophages into adipose tissue. J Biol Chem. 2008;283(33):22620–7.

    Article  PubMed  CAS  Google Scholar 

  61. Zhang Y, Guo KY, Diaz PA, Heo M, Leibel RL. Determinants of leptin gene expression in fat depots of lean mice. Am J Physiol Regul Integr Comp Physiol. 2002;282(1):R226–234.

    PubMed  CAS  Google Scholar 

  62. Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;27(5):412–21.

    Article  PubMed  CAS  Google Scholar 

  63. Wang HN, Wang YR, Liu GQ, et al. Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease. World J Gastroenterol. 2008;14(47):7240–6.

    Article  PubMed  CAS  Google Scholar 

  64. Musso G, Gambino R, Biroli G, et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2005;100(11):2438–46.

    Article  PubMed  CAS  Google Scholar 

  65. Valenti L, Fracanzani AL, Dongiovanni P, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology. 2002;122(2):274–80.

    Article  PubMed  CAS  Google Scholar 

  66. Castrillo A, Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol. 2004;20:455–80.

    Article  PubMed  CAS  Google Scholar 

  67. Walczak R, Joseph SB, Laffitte BA, Castrillo A, Pei L, Tontonoz P. Transcription of the vascular endothelial growth factor gene in macrophages is regulated by liver X receptors. J Biol Chem. 2004;279(11):9905–11.

    Article  PubMed  CAS  Google Scholar 

  68. Joseph SB, Bradley MN, Castrillo A, et al. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell. 2004;119(2):299–309.

    Article  PubMed  CAS  Google Scholar 

  69. Wouters K, van Gorp PJ, Bieghs V, et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology. 2008;48(2):474–86.

    Article  PubMed  Google Scholar 

  70. Ikejima K, Takei Y, Honda H, et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology. 2002;122(5):1399–410.

    Article  PubMed  CAS  Google Scholar 

  71. Bridle KR, Li L, O’Neill R, Britton RS, Bacon BR. Coordinate activation of intracellular signaling pathways by insulin-like growth factor-1 and platelet-derived growth factor in rat hepatic stellate cells. J Lab Clin Med. 2006;147(5):234–41.

    Article  PubMed  CAS  Google Scholar 

  72. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis. 2001;21(3):311–35.

    Article  PubMed  CAS  Google Scholar 

  73. Yamaguchi K, Yang L, McCall S, et al. Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis. Hepatology. 2008;47(2):625–35.

    Article  PubMed  CAS  Google Scholar 

  74. Siegmund SV, Uchinami H, Osawa Y, Brenner DA, Schwabe RF. Anandamide induces necrosis in primary hepatic stellate cells. Hepatology. 2005;41(5):1085–95.

    Article  PubMed  CAS  Google Scholar 

  75. Hazra S, Xiong S, Wang J, et al. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem. 2004;279(12):11392–401.

    Article  PubMed  CAS  Google Scholar 

  76. Rangwala SM, Lazar MA. Transcriptional control of adipogenesis. Annu Rev Nutr. 2000;20:535–59.

    Article  PubMed  CAS  Google Scholar 

  77. Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol. 2005;45:605–28.

    Article  PubMed  CAS  Google Scholar 

  78. Julien B, Grenard P, Teixeira-Clerc F, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology. 2005;128(3):742–55.

    Article  PubMed  CAS  Google Scholar 

  79. Younossi ZM, Gorreta F, Ong JP, et al. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int. 2005;25(4):760–71.

    Article  PubMed  CAS  Google Scholar 

  80. Namikawa C, Shu-Ping Z, Vyselaar JR, et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol. 2004;40(5):781–6.

    Article  PubMed  CAS  Google Scholar 

  81. Gambino R, Cassader M, Pagano G, Durazzo M, Musso G. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? Hepatology. 2007;45(5):1097–107.

    Article  PubMed  CAS  Google Scholar 

  82. Cho YM, Youn BS, Chung SS, et al. Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin concentrations in humans. Diabetologia. 2004;47(3):559–65.

    Article  PubMed  CAS  Google Scholar 

  83. Younossi ZM, Afendy A, Stepanova M, et al. Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C. Liver Int. 2009;29(9):1403–12.

    Article  PubMed  CAS  Google Scholar 

  84. Greco D, Kotronen A, Westerbacka J, et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol. 2008;294(5):G1281–1287.

    Article  PubMed  CAS  Google Scholar 

  85. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461–5.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Gastroenterology and Hepatology, Virginia Commonwealth University, Richmond, VA, USA

    Arun J. Sanyal

Authors
  1. Onpan Cheung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arun J. Sanyal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arun J. Sanyal .

Editor information

Editors and Affiliations

  1. School of Medicine, Dept. Pathology, University of Pittsburgh, 200 Lothrop Street, S421-BST, Pittsburgh, 15261, Pennsylvania, USA

    Satdarshan P. S. Monga

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Cheung, O., Sanyal, A.J. (2011). Nonalcoholic Fatty Liver Disease. In: Monga, S. (eds) Molecular Pathology of Liver Diseases. Molecular Pathology Library, vol 5. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-7107-4_34

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-7107-4_34

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4419-7106-7

  • Online ISBN: 978-1-4419-7107-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation